{"id":479560,"date":"2021-04-21T08:31:08","date_gmt":"2021-04-21T12:31:08","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-selects-lifesci-advisors-as-investor-relations-agent-of-record\/"},"modified":"2021-04-21T08:31:08","modified_gmt":"2021-04-21T12:31:08","slug":"immunoprecise-selects-lifesci-advisors-as-investor-relations-agent-of-record","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-selects-lifesci-advisors-as-investor-relations-agent-of-record\/","title":{"rendered":"ImmunoPrecise Selects LifeSci Advisors as Investor Relations Agent of Record"},"content":{"rendered":"

<\/p>\n

ImmunoPrecise Selects LifeSci Advisors as Investor Relations Agent of Record<\/b><\/p>\n

VICTORIA, British Columbia–(BUSINESS WIRE<\/a>)–
\nIMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, today announced that it has selected and retained LifeSci Advisors as investor relations agent of record.\n<\/p>\n

\nJennifer Bath, President and CEO of ImmunoPrecise Antibodies commented, \u201cWe are pleased to partner with LifeSci Advisors for our investor relations advisory needs during this important stage of our Company\u2019s evolution. With over 500 clients under contract globally, we look forward to continuing our discovery and development of proprietary novel antibodies while providing CRO services to 70% of the top 20 pharma.\u201d\n<\/p>\n

\nLifeSci Advisors (\u201cLSA\u201d), with over 250 employees and a local presence that spans, New York, Chicago, Boston, London, Geneva, Paris, and Tel-Aviv, provides life science companies comprehensive solutions to communications and investor outreach. Taking a partner approach, LSA increases client visibility within the investment community and educates investors on opportunities with its clients through non-deal roadshow planning and execution, KOL Events\/R&D Days, and corporate communications.\n<\/p>\n

About ImmunoPrecise Antibodies Ltd.<\/b><\/p>\n

\nIPA is an innovation-driven, technology platform company that supports its pharmaceutical and biotechnology company partners in their quest to discover and develop novel, therapeutic antibodies against all classes of disease targets. The Company aims to transform the conventional, multi-vendor, product development model by bringing innovative and high-throughput, data-driven technologies to its partners, incorporating the advantages of diverse antibody repertoires with the Company\u2019s therapeutic antibody discovery suite of technologies, to exploit antibodies of broad epitope coverage, multiple antibody formats, valency and size, and to discover antibodies against multiple\/rare epitopes. For further information, visit www.immunoprecise.com<\/a><\/span> or contact solutions@immunoprecise.com<\/a><\/span><\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20210421005374\/en\/<\/a><\/span><\/p>\n

\nInvestors:
\n
LifeSci Advisors
\n
John Mullaly
\n
Email: jmullaly@lifesciadvisors.com<\/a><\/p>\n

KEYWORDS:<\/b> North America Canada<\/p>\n

INDUSTRY KEYWORDS:<\/b> Science Other Science Biotechnology Research Pharmaceutical General Health Health Infectious Diseases<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

ImmunoPrecise Selects LifeSci Advisors as Investor Relations Agent of Record VICTORIA, British Columbia–(BUSINESS WIRE)– IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, today announced that it has selected and retained LifeSci Advisors as investor relations agent of record. Jennifer Bath, President and CEO of ImmunoPrecise Antibodies commented, \u201cWe are pleased to partner with LifeSci Advisors for our investor relations advisory needs during this important stage of our Company\u2019s evolution. With over 500 clients under contract globally, we look forward to continuing our discovery and development of proprietary novel antibodies while providing CRO services to 70% of the top 20 pharma.\u201d LifeSci Advisors (\u201cLSA\u201d), with over 250 employees … <\/p>\n

Continue reading “ImmunoPrecise Selects LifeSci Advisors as Investor Relations Agent of Record”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-479560","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nImmunoPrecise Selects LifeSci Advisors as Investor Relations Agent of Record - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-selects-lifesci-advisors-as-investor-relations-agent-of-record\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ImmunoPrecise Selects LifeSci Advisors as Investor Relations Agent of Record - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"ImmunoPrecise Selects LifeSci Advisors as Investor Relations Agent of Record VICTORIA, British Columbia–(BUSINESS WIRE)– IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, today announced that it has selected and retained LifeSci Advisors as investor relations agent of record. Jennifer Bath, President and CEO of ImmunoPrecise Antibodies commented, \u201cWe are pleased to partner with LifeSci Advisors for our investor relations advisory needs during this important stage of our Company\u2019s evolution. With over 500 clients under contract globally, we look forward to continuing our discovery and development of proprietary novel antibodies while providing CRO services to 70% of the top 20 pharma.\u201d LifeSci Advisors (\u201cLSA\u201d), with over 250 employees … Continue reading "ImmunoPrecise Selects LifeSci Advisors as Investor Relations Agent of Record"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-selects-lifesci-advisors-as-investor-relations-agent-of-record\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-21T12:31:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210421005374r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunoprecise-selects-lifesci-advisors-as-investor-relations-agent-of-record\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunoprecise-selects-lifesci-advisors-as-investor-relations-agent-of-record\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"ImmunoPrecise Selects LifeSci Advisors as Investor Relations Agent of Record\",\"datePublished\":\"2021-04-21T12:31:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunoprecise-selects-lifesci-advisors-as-investor-relations-agent-of-record\\\/\"},\"wordCount\":337,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunoprecise-selects-lifesci-advisors-as-investor-relations-agent-of-record\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210421005374r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunoprecise-selects-lifesci-advisors-as-investor-relations-agent-of-record\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunoprecise-selects-lifesci-advisors-as-investor-relations-agent-of-record\\\/\",\"name\":\"ImmunoPrecise Selects LifeSci Advisors as Investor Relations Agent of Record - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunoprecise-selects-lifesci-advisors-as-investor-relations-agent-of-record\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunoprecise-selects-lifesci-advisors-as-investor-relations-agent-of-record\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210421005374r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2021-04-21T12:31:08+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunoprecise-selects-lifesci-advisors-as-investor-relations-agent-of-record\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunoprecise-selects-lifesci-advisors-as-investor-relations-agent-of-record\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunoprecise-selects-lifesci-advisors-as-investor-relations-agent-of-record\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210421005374r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210421005374r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunoprecise-selects-lifesci-advisors-as-investor-relations-agent-of-record\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ImmunoPrecise Selects LifeSci Advisors as Investor Relations Agent of Record\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ImmunoPrecise Selects LifeSci Advisors as Investor Relations Agent of Record - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-selects-lifesci-advisors-as-investor-relations-agent-of-record\/","og_locale":"en_US","og_type":"article","og_title":"ImmunoPrecise Selects LifeSci Advisors as Investor Relations Agent of Record - Market Newsdesk","og_description":"ImmunoPrecise Selects LifeSci Advisors as Investor Relations Agent of Record VICTORIA, British Columbia–(BUSINESS WIRE)– IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, today announced that it has selected and retained LifeSci Advisors as investor relations agent of record. Jennifer Bath, President and CEO of ImmunoPrecise Antibodies commented, \u201cWe are pleased to partner with LifeSci Advisors for our investor relations advisory needs during this important stage of our Company\u2019s evolution. With over 500 clients under contract globally, we look forward to continuing our discovery and development of proprietary novel antibodies while providing CRO services to 70% of the top 20 pharma.\u201d LifeSci Advisors (\u201cLSA\u201d), with over 250 employees … Continue reading \"ImmunoPrecise Selects LifeSci Advisors as Investor Relations Agent of Record\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-selects-lifesci-advisors-as-investor-relations-agent-of-record\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-21T12:31:08+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210421005374r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-selects-lifesci-advisors-as-investor-relations-agent-of-record\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-selects-lifesci-advisors-as-investor-relations-agent-of-record\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"ImmunoPrecise Selects LifeSci Advisors as Investor Relations Agent of Record","datePublished":"2021-04-21T12:31:08+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-selects-lifesci-advisors-as-investor-relations-agent-of-record\/"},"wordCount":337,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-selects-lifesci-advisors-as-investor-relations-agent-of-record\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210421005374r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-selects-lifesci-advisors-as-investor-relations-agent-of-record\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-selects-lifesci-advisors-as-investor-relations-agent-of-record\/","name":"ImmunoPrecise Selects LifeSci Advisors as Investor Relations Agent of Record - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-selects-lifesci-advisors-as-investor-relations-agent-of-record\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-selects-lifesci-advisors-as-investor-relations-agent-of-record\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210421005374r1&sid=flmnd&distro=nx&lang=en","datePublished":"2021-04-21T12:31:08+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-selects-lifesci-advisors-as-investor-relations-agent-of-record\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-selects-lifesci-advisors-as-investor-relations-agent-of-record\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-selects-lifesci-advisors-as-investor-relations-agent-of-record\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210421005374r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210421005374r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-selects-lifesci-advisors-as-investor-relations-agent-of-record\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"ImmunoPrecise Selects LifeSci Advisors as Investor Relations Agent of Record"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/479560","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=479560"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/479560\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=479560"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=479560"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=479560"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}